Illustrative image – not actual.The government has asked the Department of Biotechnology and Indian Petrochemicals Corporation Ltd (IPCL) to revive a Rs.300 crore vaccine project at Gurgaon in Haryana, originally proposed over a decade ago.
The project was originally proposed as a joint venture between IPCL, the Department of Biotechnology and French pharmaceutical company, Pasteur Merieux Serums Vaccines (PMSV). However, PMSV quit the project as an equity partner, around two years ago. The Department of Biotechnology is planning to bring in Hyderabad-based pharmaceutical company Bharat Biotech International Ltd to replace PMSV. Bharat Biotech would bring in technology for the project.
Cadila Pharma, which had evinced interest in the project, had later backed out.
The project, conceived in the late 1980s, was supposed to manufacture injectable polio vaccine. However, at that time, oral polio vaccine became more popular vis-à-vis injectables, as the latter was more expensive. The delay in implementation of the project led PMSV to quit in the late 1990s. The equity holding of PMSV was handed over to the Department of Biotechnology and IPCL. The latter is the project financier.
According to Mr Ashok Chawla, Chairman and Managing Director of IPCL, instead of injectable polio vaccine, some other products may be considered for the project.
